|
End-of-day quote
Korea S.E.
2026-09-10
|
5-day change | 1st Jan Change | ||
| 180,800.00 KRW | -1.26% |
|
-3.37% | +4.88% |
| 09-06 | Celltrion Secures IND Application Amendment Approvals for CT-P44, CT-P51 Phase 3 Trial | MT |
| 08-31 | Celltrion, Inc. authorizes a Buyback Plan. | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 32.79B | |||||
| 46.38B | |||||
| 44.51B | - | - | - | - | - |
| 42.3B | |||||
| 39.91B | |||||
| 17.13B | - |
- Stock Market
- Stocks
- A068270 Stock
- Charts Celltrion, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
